Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2010
09/16/2010WO2010057006A9 Azaquinolinone derivatives and uses thereof
09/16/2010WO2010056672A3 Butylammonium modulators of fatty acid transport
09/16/2010WO2010054286A3 Substituted hydroxyphenylamine compounds
09/16/2010WO2010033587A3 Methods for treating progressive multiple sclerosis
09/16/2010WO2010021697A3 Antibodies to ccr2
09/16/2010US20100235931 Novel Neurological Function of mPKCI
09/16/2010US20100234468 Novel process
09/16/2010US20100234463 Method for Identifying Modulators of Gamma Secretase or Notch
09/16/2010US20100234461 Compositions For Improved Oxidative Status In Companion
09/16/2010US20100234448 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100234441 Novel compounds
09/16/2010US20100234439 Therapeutic agents
09/16/2010US20100234438 Therapeutic agents
09/16/2010US20100234433 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
09/16/2010US20100234429 Substituted nicotinamides as kcnq2/3 modulators
09/16/2010US20100234428 Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators
09/16/2010US20100234427 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
09/16/2010US20100234426 Phenylpropionamide Compounds and the Use Thereof
09/16/2010US20100234424 Derivatives of n-phenyl(piperidine-2-yl) methyl benzamide preparation method thereof and applications of same in therapeutics
09/16/2010US20100234421 Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators
09/16/2010US20100234420 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
09/16/2010US20100234419 Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
09/16/2010US20100234417 Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
09/16/2010US20100234416 Use of huperzine for disorders
09/16/2010US20100234413 Compositions and methods for prophylaxis and treatment of addictions
09/16/2010US20100234412 Buprenorphine Derivatives and Uses Thereof
09/16/2010US20100234406 Compounds and compositions as c-kit and pdgfr kinase inhibitors
09/16/2010US20100234404 P-38 Kinase Inhibitors
09/16/2010US20100234402 Methods and compositions for treating spinal muscular atrophy
09/16/2010US20100234397 Enzyme inhibitors
09/16/2010US20100234389 Amide compound
09/16/2010US20100234387 Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals
09/16/2010US20100234386 Quinoxaline derivatives as pi3 kinase inhibitors
09/16/2010US20100234385 Compsition Containing Biopterin and Method for Using The Same
09/16/2010US20100234384 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
09/16/2010US20100234380 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
09/16/2010US20100234379 Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity
09/16/2010US20100234377 Piperazine compounds for the inhibition of haematopoietic prostaglandin d synthase
09/16/2010US20100234374 Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors
09/16/2010US20100234372 Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
09/16/2010US20100234370 Pharmaceutical compounds
09/16/2010US20100234369 5-cyanothienopyridines for the treatment of tumours
09/16/2010US20100234367 7-cycloalkylaminoquinolones as gsk-3 inhibitors
09/16/2010US20100234365 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
09/16/2010US20100234361 Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions
09/16/2010US20100234360 Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations
09/16/2010US20100234358 Neramexane for the treatment of nystagmus
09/16/2010US20100234357 Benzofuran derivatives
09/16/2010US20100234353 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
09/16/2010US20100234349 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
09/16/2010US20100234347 Substituted Pteridines substituted with a Four-Membered Heterocycle
09/16/2010US20100234345 Novel compounds as cannabinoid receptor ligands
09/16/2010US20100234343 Inhibitors of ion channels
09/16/2010US20100234341 Substituted pyrimidines as adenosine receptor antagonists
09/16/2010US20100234335 Neurosteroid compounds
09/16/2010US20100234331 Hexahydro-cyclooctyl pyrazole cannabinoid modulators
09/16/2010US20100234326 Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
09/16/2010US20100234324 Quinazolinamide derivatives
09/16/2010US20100234315 Compositions and methods for treating psychiatric and behavioral disorders
09/16/2010US20100234306 Use of a peptide as a therapeutic agent
09/16/2010US20100234295 Treating Alzheimer's Disease And Osteoporosis And Reducing Aging
09/16/2010US20100234293 Novel Neurotrophic Factors
09/16/2010US20100234288 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER
09/16/2010US20100234278 Prophylactic and/or therapeutic agents for peripheral neuropathy
09/16/2010US20100234275 Use Of A High Molecular Weight Extracellular Hemoglobin For The Manufacture Of A Medicament For Treating And/Or Preventing Diseases By Inhibition Of Calcium
09/16/2010US20100234273 Light-activated cation channel and uses thereof
09/16/2010US20100233819 Robo: a novel family of polypeptides and nucleic acids
09/16/2010US20100233810 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
09/16/2010US20100233722 Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA
09/16/2010US20100233304 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
09/16/2010US20100233303 Prevention and treatment of disorders connected to impaired neurotransmission
09/16/2010US20100233294 Use of tellurium compounds for inhibition of interleukin-converting enzyme
09/16/2010US20100233281 Process for decreasing environmental pollutants in an oil or a fat.
09/16/2010US20100233280 Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
09/16/2010US20100233279 Compositions And Methods Comprising Analogues Of Radicicol A
09/16/2010US20100233259 Dosage form of ropinirole
09/16/2010US20100233257 Low dose sublingual tablets of opioid analgesics and preparation process
09/16/2010US20100233255 Combination of trazine derivatives and insulin secretion stimulators
09/16/2010US20100233244 Smoking Withdrawal Combination Wafer
09/16/2010US20100233230 Sol-gel nanostructured titania reservoirs for use in the controlled release of drugs in the central nervous system and method of synthesis
09/16/2010US20100233226 Drug-eluting nanowire array
09/16/2010US20100233217 Organic compounds
09/16/2010US20100233180 Antibodies that bind to an epitope on the huntington's disease protein
09/16/2010US20100233176 Methods and systems for predicting misfolded protein epitopes
09/16/2010US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides
09/16/2010US20100233157 Human antibodies against human fas and their use
09/16/2010US20100233156 Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
09/16/2010US20100233153 Novel gene disruptions, compositions and the methods relating thereto
09/16/2010US20100233143 Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells
09/16/2010US20100233117 Adjuvant combination formulations
09/16/2010US20100233095 Conformationally dynamic peptides
09/16/2010US20100233086 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
09/16/2010US20100233079 Dual Variable Domain Immunoglobulins and Uses Thereof
09/16/2010CA2792484A1 Implantable device for long-term delivery of drugs
09/16/2010CA2755120A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors
09/16/2010CA2755004A1 Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
09/16/2010CA2755002A1 Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators
09/16/2010CA2754943A1 Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators
09/16/2010CA2754934A1 Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators